Non-Invasive Cancer Diagnostics Market Expected To Propel Market, Key Futuristic Trends And Competitive Landscape Appraised By Global Players Roche Diagnostics, Hologic Inc., Qiagen, Gen-Probe Inc., Digene Corporation, Abbott Molecular

Non-invasive cancer diagnostics are procedures used for the identification of cancer without incision in the body. Detection and treatment of cancer at early stages are important for long-term survival. Non-invasive cancer detection method is found to be an increasing choice of interest, owing to its painless or minimal pain method of diagnostic coupled with more accurate results.

Get Exclusive Sample Report at: https://bit.ly/2H4cdB8

Molecular based diagnostic methods are expected to increase during the forecast period due to launches of new biomarker based detection methods. Moreover, factors like increasing incidence of cancer, increasing cancer screening rate, government initiatives, and emerging technologies such as next generation sequencing are expected to drive the market during the forecast period.

Non-Invasive Cancer Diagnostics Market Drivers:

Increasing incidence of cancer is expected to be a major factor driving growth of non-invasive cancer diagnostics market. Cancer is a major factor impacting the world economy. For instance, according to the National Cancer Institute (NIH), cancer incidence was 439.2 per 100,000 individuals based on the cancer cases that occurred between 2011 and 2015. The same source estimated that rate of cancer survivors in the U.S. were 15.5 million, which is expected to increase to 20.3 million by 2026.

Increasing rate of cancer detection will also boost the non-invasive cancer diagnostics market growth. According to the U.S. Breast Cancer Surveillance Consortium (BCSC) researchers, the rate of cancer detection increased to 34.7 per 1,000 individuals in 2013, as compared to 25.3 per 1,000 individuals in 2005. Furthermore, governmental and non-governmental organizations are engaged in raising awareness for breast and cervical cancer as well as conducts screening programme. The National Institute for Health and Care Excellence (NICE) is involved in improving diagnosis rate by revising draft guideline for early cancer detection. Moreover, increasing cancer studies for cancer drug development will boost the non-invasive cancer diagnostics market growth. In 2016, NCI's Center to Reduce Cancer Health Disparities launched the National ‘Screen to Save’ Colorectal Cancer Outreach and Screening Initiative. The initiative was aimed at increasing colorectal cancer screening rate.

Non-Invasive Cancer Diagnostics Market Taxonomy:

On the basis of technology, the non-invasive cancer diagnostics market is segmented into:
Clinical Chemistry, Spectroscopy, Immunoassay, Molecular Diagnostics, Others

On the basis of cancer type, the non-invasive cancer diagnostics market is segmented into:
Lung Cancer,Breast Cancer,Solid Tumors,Blood Cancer,Other Cancer Type

On the basis of region, the non-invasive cancer diagnostics market is segmented into:
North America,Europe,Latin America,Asia Pacific,Middle East,Africa

Global Key Players:

Some of the key players operating in the global non-invasive cancer diagnostics market include
Roche Diagnostics,Hologic Inc.,Qiagen,Gen-Probe Inc.,Digene Corporation,Abbott Molecular,IVDiagnostics,Laboratory Corporation of America Holdings,OncoCyte Corporation,Arquer Diagnostics Ltd. ,Affymetrix Inc.

Non-Invasive Cancer Diagnostics Market - Regional Analysis:

On the basis of region, the global non-invasive cancer diagnostics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the non-invasive diagnostics market, owing to increasing incidence of cancer, increasing technological advancement, better reimbursement scenario, and governmental initiatives for screening of cancer in early stages. For instance, the American Cancer Society Guidelines for the early detection of cancer offers various screening plans at different ages. For example, the guidelines suggest that women between the age of 40 and 44 must screen for breast cancer annually.

Browse Research Report At: https://bit.ly/2NtHChs

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.